Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder. PARTICIPANTS: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority. CONCLUSIONS: ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As with Cushing’s disease, it may be helpful to use a cortisol synthesis blocking drug while waiting for definitive treatment (18) and in cases where definitive treatment is not possible.”
From ACTH Antagonists (2016) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Once a diagnosis is conclusively made, the optimal treatment is surgical removal of the tumor – ideally preserving the remaining pituitary function.”
From ACTH Antagonists (2016) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“excess cortisol secretion by unilateral adrenocortical tumors or by bilateral adrenal hyperplasia or dysplasia (1).”
BackgroundInfluentialSelf-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884 · cited 1×
“However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Ilias, I., Torpy, D. J., Pacak, K., Mullen, N., Wesley, R. A., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2527 · Cited by 713
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Isidori, A. M., Kaltsas, G. A., Pozza, C., Frajese, V., Newell-Price, J., Reznek, R. H., Jenkins, P. J., Monson, J. P., Grossman, A. B., & Besser, G. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1542 · Cited by 522
Self-citationThe hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment
Lindsay, J. R., & Nieman, L. K. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0025 · Cited by 449 · cited 1×
“Detection of Cushing’s syndrome usually occurs late in gestation, and the diagnosis is complicated by the signs of normal pregnancy, such as central weight gain, facial plethora, and pigmentation (101) and the normal physiological changes in the maternal HPA axis.”
BackgroundSelf-citationPosterior retroperitoneoscopic adrenalectomy–results of 560 procedures in 520 patients
Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., Ommer, A., Groeben, H., Peitgen, K., Janssen, O. E., et al. (2006) · Surgery · doi:10.1016/j.surg.2006.07.039 · Cited by 425
Self-citationRisk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413 · cited 1×
“The risk of second tumor formation after pituitary radiation is considered to be in the range of 1–2% (39), but this may not be due to the radiotherapy per se.”
Background
Research works printed but not linked: 1
- 52. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F 1986 Prolonged - treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 14:485-486
Cited by
Items 201–300 of 863
Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.
Glackin, L., Leen, G., Elnazir, B., & Greally, P. (2009) · PubMed · Cited by 39
Cabergoline treatment for recurrent Cushing’s disease during pregnancy
Nakhleh, A., Saiegh, L., Reut, M., Sheikh‐Ahmad, M., Wirsansky, I., & Shechner, C. (2016) · HORMONES · doi:10.14310/horm.2002.1685 · Cited by 44
Zoli, M., Staartjes, V. E., Guaraldi, F., Friso, F., Rustici, A., Asioli, S., Sollini, G., Pasquini, E., Regli, L., Serra, C., et al. (2020) · Neurosurgical FOCUS · doi:10.3171/2020.3.focus2060 · Cited by 40
“NEUROSURGICAL FOCUS Neurosurg Focus 48 (6):E5, 2020”
Fleseriu, M., Auchus, R. J., Greenman, Y., Zacharieva, S., Geer, E. B., Salvatori, R., Pivonello, R., Feldt‐Rasmussen, U., Kennedy, L., Buchfelder, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0506 · Cited by 40
Self-citationOcchi, G., Regazzo, D., Albiger, N. M. E., Ceccato, F., Ferasin, S., Scanarini, M., Denaro, L., Cosma, C., Plebani, M., Cassarino, M. F., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1820 · Cited by 39
Self-citationMacKenzie Feder, J., Bourdeau, I., Vallette, S., Beauregard, H., Ste-Marie, L.-G., & Lacroix, A. (2014) · Pituitary · doi:10.1007/s11102-013-0539-4 · Cited by 38
Self-citationEarly promising results for the endoscopic surgical treatment of Cushing’s disease
Berker, M., Işıkay, İ., Berker, D. S., Bayraktar, M., & Gürlek, A. (2013) · Neurosurgical Review · doi:10.1007/s10143-013-0506-6 · Cited by 38
Mehta, G. U., Sheehan, J. P., & Vance, M. L. (2013) · Journal of neurosurgery · doi:10.3171/2013.7.jns13389 · Cited by 38
Self-citationMilian, M., Teufel, P., Honegger, J. B., Gallwitz, B., Schnauder, G., & Psaras, T. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04191.x · Cited by 38
Update on radiation therapy in patients with Cushing’s disease
Tritos, N. A., & Biller, B. M. K. (2014) · Pituitary · doi:10.1007/s11102-014-0615-4 · Cited by 37
“cessful in inducing remission in approximately 55 % of patients [1].”
BackgroundSelf-citationIndividualized medical treatment options in Cushing disease
Gilis‐Januszewska, A., Bogusławska, A., Rzepka, E., Ziaja, W., & Hubalewska–Dydejczyk, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1060884 · Cited by 41
“In a pharmacological study, the presence of relacorilant led to a greater than 8-fold increase in midazolam overall exposure (51).”
BackgroundTherapeutic options after surgical failure in Cushing's disease: A critical review
Rubinstein, G., Oßwald, A., Zopp, S., Ritzel, K., Theodoropoulou, M., Beuschlein, F., & Reincke, M. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.004 · Cited by 43
Sun, Y., Sun, Q., Fan, C., Shen, J., Zhao, W., Guo, Y., Su, T., Wang, W., Ning, G., & Bian, L. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04279.x · Cited by 36
Tagliati, F., Gentilin, E., Buratto, M., Molè, D., Uberti, E. C. D., & Zatelli, M. C. (2010) · Endocrinology · doi:10.1210/en.2010-0441 · Cited by 36
van den Bosch, O. F. C., Stades, A. M. E., & Zelissen, P. M. J. (2014) · Clinical Endocrinology · doi:10.1111/cen.12286 · Cited by 35
Selective progesterone receptor modulators
Whitaker, L. H. R., Williams, A. R. W., & Critchley, H. O. D. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000082 · Cited by 35
“However, approximately 20% will relapse [33], and radiotherapy, whilst often achieving control, can take several years to become effective.”
BackgroundCushing's disease: current medical therapies and molecular insights guiding future therapies
Lau, D., Rutledge, C., & Aghi, M. K. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.10.focus14700 · Cited by 38
Pharmacological management of severe Cushing’s syndrome: the role of etomidate
Pence, A., McGrath, M., Lee, S. L., & Raines, D. E. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058583 · Cited by 37
Transsphenoidal Surgery for Cushing Disease After Nondiagnostic Inferior Petrosal Sinus Sampling
Sheth, S. A., Mian, M. K., Neal, J., Tritos, N. A., Nachtigall, L., Klibanski, A., Biller, B. M. K., & Swearingen, B. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31824f8e2e · Cited by 35
“2), adrenal adenoma (3-10), CRH-secreting bronchial carcinoid (pre-CRH ratio,”
Self-citationShimon, I., Rot, L., & Inbar, E. (2012) · Pituitary · doi:10.1007/s11102-012-0427-3 · Cited by 35
Advances in understanding pituitary tumors
Kopczak, A., Renner, U., & Stalla, G. K. (2014) · F1000Prime Reports · doi:10.12703/p6-5 · Cited by 35
“Surgical treatment is the first-line treatment in pituitary adenomas — except for prolactinomas, where dopamine agonists are recommended as treatment of choice [20,21].”
BackgroundSelf-citationOßwald, A., Deutschbein, T., Berr, C., Plomer, E., Mickisch, A., Ritzel, K., Schopohl, J., Beuschlein, F., Faßnacht, M., Hahner, S., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0212 · Cited by 35
Solari, D., Pivonello, R., Caggiano, C., Guadagno, E., Chiaramonte, C., Miccoli, G., Cavallo, L. M., De, M. D. B., Colao, A., & Cappabianca, P. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.03.049 · Cited by 37
Self-citationPituitary Surgery for Cushing’s Disease
Buchfelder, M., & Schlaffer, S. M. (2010) · Neuroendocrinology · doi:10.1159/000314223 · Cited by 35
“Although, to date in many patients tiny tumors can be directly depicted by sophisticated MR imaging studies, still up to 50p of these tumors escape radiological detection because of their minute size. The aim of this article is to briefly review the present status of neurosurgical operations for Cushing’s disease. The…”
BackgroundSelf-citationMolecular basis of pharmacological therapy in Cushing’s disease
Ferone, D., Pivonello, C., Vitale, G., Zatelli, M. C., Colao, A., & Pivonello, R. (2013) · Endocrine · doi:10.1007/s12020-013-0098-5 · Cited by 35
Self-citationFein, H. G., Vaughan, T. B., Kushner, H., Cram, D., & Nguyen, D. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0059-5 · Cited by 32
“Given that longterm recurrence of hypercortisolism after initial surgical success following transsphenoidal pituitary surgery in patients with Cushing’s disease (CD) has been reported in up to 66 % of patients followed postoperatively for a mean duration of 14 years (range 1–37 years) [11, 18–22], recurrent disease is…”
Melmed, S. K., & Kleinberg, D. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00009-2 · Cited by 38
Self-citationZhang, W., Sun, M., Fan, Y., Wang, H., Feng, M., Zhou, S. K., & Wang, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.635795 · Cited by 34
“According to a consensus statement, the first-line treatment option for CD is transsphenoidal surgery (TSS) (2).”
BackgroundBonnet-Serrano, F., Poirier, J., Vaczlavik, A., Laguillier, C., Blanchet, B., Baron, S., Guignat, L., Bessiène, L., Bricaire, L., Groussin, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0208 · Cited by 37
Self-citationAbdelmannan, D., Chaiban, J., Selman, W. R., & Arafah, B. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3910 · Cited by 34
Yamada, S., Inoshita, N., Fukuhara, N., Yamaguchi‐Okada, M., Nishioka, H., Takeshita, A., Suzuki, H., Itô, J., & Takeuchi, Y. (2015) · Endocrine Journal · doi:10.1507/endocrj.15-0463 · Cited by 39
Daniel, E., & Newell-Price, J. D. C. (2013) · Medicine · doi:10.1016/j.mpmed.2013.06.007 · Cited by 37
Self-citationGeer, E. B., Shafiq, I., Gordon, M. B., Bonert, V., Ayala, A., Swerdloff, R. S., Katznelson, L., Lalazar, Y., Manuylova, E., Pulaski-Liebert, K. J., et al. (2017) · Endocrine Practice · doi:10.4158/ep171787.or · Cited by 33
Self-citationManagement of recurrent Cushing’s disease
Liubinas, S. V., del Porto, L. A., & Kaye, A. H. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.05.001 · Cited by 35
“Persistent morning serum cortisol of less than 50 nmol/L are associated with low recurrence rates of approximately 10% at 10 years.(25) Similarly, the need for, and duration of, replacement cortisol therapy is strongly correlated with a lower probability of recurrence.”
InfluentialPrognostic Factors of Long-Term Remission After Surgical Treatment of Cushing’s Disease
Ioachimescu, A. G. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.002 · Cited by 36
Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field
Chang, S. W., Donoho, D. A., & Zada, G. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03062-2 · Cited by 34
Locatelli, D., Veiceschi, P., Castelnuovo, P., Tanrıöver, N., Evliyaoğlu, O., Canaz, H., Uğurlar, D., & Gazioğlu, N. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04179-z · Cited by 33
The role of integrated 18F-FDG PET/CT in identification of ectopic ACTH secretion tumors
Xu, H., Zhang, M., Zhai, G., Zhang, M., Ning, G., & Li, B. (2009) · Endocrine · doi:10.1007/s12020-009-9247-2 · Cited by 33
“Generally speaking, early diagnosis of EAS and curative tumor resection may lead to a favorable prognosis, because the optimal treatment of EAS tumors is surgical resection of the corticotrophin-secreting tumor [5, 6 ]. Our patients underwent EAS tumor resection, all of them showed symptom remission but one patient di…”
BackgroundManagement of Incidentally Found Nonfunctional Pituitary Tumors
Molitch, M. E. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.003 · Cited by 33
Cushing’s disease: Results of treatment and factors affecting outcome
Ammini, A. C., Bhattacharya, S., Sahoo, J. P., Philip, J., Tandon, N., Goswami, R., Jyotsna, V. P., Khadgawat, R., Chumber, S., Seth, A., et al. (2011) · HORMONES · doi:10.14310/horm.2002.1312 · Cited by 34
“Cushing’s syndrome (CS) is a complex endocrine disorder with potential for serious consequences if not promptly and adequately treated.(1-10) The clini-”
BackgroundMethodMedical Management of Persistent and Recurrent Cushing Disease
Fleseriu, M. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.012 · Cited by 34
The New Molecular Landscape of Cushing's Disease
Sbiera, S., Deutschbein, T., Weigand, I., Reincke, M., Faßnacht, M., & Allolio, B. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.08.003 · Cited by 32
“Transsphenoidal surgery is the treatment of choice, resulting in high initial remission rates [15].”
BackgroundCapatina, C. A.-M., Hinojosa‐Amaya, J. M., Poiană, C., & Fleseriu, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1802243 · Cited by 34
Liu, Z., Zhang, X., Wang, Z., You, H., Li, M. L., Feng, F., & Jin, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-71628-0 · Cited by 32
The use of mass spectrometry to improve the diagnosis and the management of the HPA axis
Monaghan, P. J., Keevil, B. G., & Trainer, P. J. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9240-1 · Cited by 28
“The measurement of cortisol day curves are used by some centres to assess normalisation of cortisol production [78] realised by a day curve mean serum cortisol between 150 and 300 nmol/L [79].”
MethodMifepristone: is there a place in the treatment of Cushing’s disease?
Carmichael, J. D., & Fleseriu, M. (2012) · Endocrine · doi:10.1007/s12020-012-9846-1 · Cited by 33
Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship With Tumor Behavior
Liu, X.-H., Feng, M., Dai, C., Bao, X., Deng, K., Yao, Y., & Wang, R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00785 · Cited by 32
Pasireotide: A Review of Its Use in Cushing’s Disease
McKeage, K. (2013) · Drugs · doi:10.1007/s40265-013-0052-0 · Cited by 33
“Cushing’s disease is caused by a pituitary adenoma that secretes excess corticotropin, which in turn stimulates the adrenal glands to secrete excess cortisol [1].”
BackgroundInfluentialKageyama, K., Asari, Y., Sugimoto, Y., Niioka, K., & Daimon, M. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0239 · Cited by 31
Fleseriu, M., & Petersenn, S. (2015) · Pituitary · doi:10.1007/s11102-014-0627-0 · Cited by 31
“Reports that ketoconazole has direct effect on ACTH have not been confirmed [3, 25].”
BackgroundInfluentialSelf-citationShin, S. S., Gardner, P. A., Ng, J., Faraji, A. H., Agarwal, N., Chivukula, S., Fernandez-Miranda, J. C., Snyderman, C. H., & Challinor, S. M. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.07.065 · Cited by 31
Trementino, L., Cardinaletti, M., Concettoni, C., Marcelli, G., Boscaro, M., & Arnaldi, G. (2014) · Pituitary · doi:10.1007/s11102-014-0582-9 · Cited by 31
“Pituitary surgery represents the first-line treatment in patients with CD but failure and recurrence are common and pharmacotherapy provides a good second-line option [1].”
BackgroundSelf-citationSrinivasan, L., Laws, E. R., Dodd, R. L., Monita, M. M., Tannenbaum, C. E., Kirkeby, K. M., Chu, O. S., Harsh, G. R., & Katznelson, L. J. (2011) · Pituitary · doi:10.1007/s11102-011-0295-2 · Cited by 31
Psaras, T., Milian, M., Hattermann, V., Will, B. E., Tatagiba, M. S., & Honegger, J. B. (2011) · PubMed · doi:10.3275/7333 · Cited by 31
Role of radiosurgery in the treatment of Cushing's disease
Losa, M., Albano, L., Bailo, M., Barzaghi, L. R., & Mortini, P. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13134 · Cited by 32
External Beam Radiation Therapy and Stereotactic Radiosurgery for Pituitary Adenomas
Sheehan, J. P., Xu, Z., & Lobo, M. J. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.011 · Cited by 30
Paraneoplastic Cushing syndrome, case-series and review of the literature
Deldycke, A., Haenebalcke, C., & Taes, Y. (2017) · Acta Clinica Belgica · doi:10.1080/17843286.2017.1373927 · Cited by 31
Pituitary Disorders in Pregnancy
Woodmansee, W. W. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.09.009 · Cited by 33
Cushing’s syndrome: an update on current pharmacotherapy and future directions
Creemers, S. G., Hofland, L. J., Lamberts, S. W. J., & Feelders, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1061995 · Cited by 31
Self-citationNew avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
Fleseriu, M., & Petersenn, S. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1151-1 · Cited by 32
Self-citationSelective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in Mice
Asagami, T., Belanoff, J. K., Azuma, J., Blasey, C. M., Clark, R. D., & Tsao, P. S. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/235389 · Cited by 32
The Endocrine System and the Heart: A Review
Rhee, S. S., & Pearce, E. N. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2010.10.016 · Cited by 46
“Medical control of hypercortisolism in nonsurgical patients may be achieved using ketoconazole, metyrapone, and/or mitotane.(50)”
BackgroundCeccato, F., Trementino, L., Barbot, M., Antonelli, G., Plebani, M., Denaro, L., Regazzo, D., Rea, F., Frigo, A. C., Concettoni, C., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13391 · Cited by 30
Self-citationMGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
Micko, A. S. G., Wöehrer, A., Höftberger, R., Vila, G., Marosi, C., Knosp, E., & Wolfsberger, S. (2017) · Pituitary · doi:10.1007/s11102-017-0829-3 · Cited by 31
Medical Treatment of Cushing Disease
Fleseriu, M. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.006 · Cited by 29
Jian, F., Chen, Y., Ning, G., Fu, W., Tang, H., Chen, X., Zhao, Y., Zheng, L., Pan, S., Wang, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7037 · Cited by 29
“Transsphenoidal surgery has been established as the first-line treatment of choice, with remission rates of 65-90% when an expert pituitary surgeon operates [5], hypercortisolism, however, persists or recurs in an important subset of patients [6, 7].”
Medical management of Cushing’s disease
Tritos, N. A., & Biller, B. M. K. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1269-1 · Cited by 30
“Patients with recurrent CD should be considered for a second pituitary operation, if an expert pituitary neurosurgeon is available [4, 17, 18].”
BackgroundInfluentialSelf-citationEmmerich, J., van Koppen, C. J., Burkhart, J. L., Hu, Q., Siebenbürger, L., Boerger, C., Scheuer, C., Laschke, M. W., Menger, M. D., & Hartmann, R. W. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00437 · Cited by 28
Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor
Lin, A. L., Donoghue, M. T. A., Wardlaw, S. L., Yang, J. T., Bodei, L., Tabar, V. S., & Geer, E. B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa649 · Cited by 31
Liu, P. Y., Lawrence-Sidebottom, D., Piotrowska, K., Zhang, W., Iranmanesh, A., Auchus, R. J., Veldhuis, J. D., & Van Dongen, H. P. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab375 · Cited by 28
Trementino, L., Michetti, G., Angeletti, A., Marcelli, G., Concettoni, C., Cardinaletti, C., Polenta, B., Boscaro, M., & Arnaldi, G. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-101347 · Cited by 30
Self-citationAyala, A. R., & Manzano, A. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1508-0 · Cited by 32
Psaras, T., Milian, M., Hattermann, V., Gerlach, C., & Honegger, J. B. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.01.027 · Cited by 30
Bilateral adrenalectomy for Cushing’s disease
Katznelson, L. J. (2015) · Pituitary · doi:10.1007/s11102-014-0633-2 · Cited by 28
“In Cushing’s disease 20–30 % of subjects require further therapy following surgery because of persistent disease [2].”
BackgroundInfluentialZieliński, G., Maksymowicz, M., Podgórski, J. K., & Olszewski, W. T. (2013) · Endocrine Pathology · doi:10.1007/s12022-013-9237-z · Cited by 28
Kakade, H., Kasaliwal, R., Khadilkar, K. S., Jadhav, S., Bukan, A., Khare, S., Budyal, S. R., Goel, A. H., Lila, A. R., Bandgar, T., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12442 · Cited by 28
Association Between Mifepristone Dose, Efficacy, and Tolerability in Patients With Cushing Syndrome
Yuen, K. C. J., Williams, G., Kushner, H., & Nguyen, D. (2015) · Endocrine Practice · doi:10.4158/ep15760.or · Cited by 28
“In patients with Cushing disease (CD), the most common form of endogenous CS, surgical success rates are variable, ranging from 65 to 90% when performed by an experienced surgeon (6,7).”
BackgroundInfluentialMelmed, S. K., & Kleinberg, D. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00009-5 · Cited by 39
Self-citationLapatinib decreases the ACTH production and proliferation of corticotroph tumor cells
Asari, Y., Kageyama, K., Sugiyama, A., Kogawa, H., Niioka, K., & Daimon, M. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0491 · Cited by 28
“This leads to osteoporosis, infections, hyperglycemia, hypertension, and atheroscle‐ rosis [3].”
BackgroundHou, B., Gao, L., Shi, L., Luo, Y., Guo, X., Young, G. S., Qin, L., Zhu, H., Lü, L., Wang, Z., et al. (2020) · Journal of neurosurgery · doi:10.3171/2019.10.jns191400 · Cited by 28
Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin, A. L., Sum, M., & DeAngelis, L. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now059 · Cited by 31
AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease
Hamrahian, A. H., Yuen, K. C. J., & Hoffman, A. R. (2014) · Endocrine Practice · doi:10.4158/ep14147.ra · Cited by 27
Currently used and investigational drugs for Cushing´s disease
Ciato, D., Mumbach, A. G., Páez-Pereda, M., & Stalla, G. K. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1266338 · Cited by 29
Self-citationZhang, K., Shen, M., Qiao, N., Chen, Z., He, W., Ma, Z., Shou, X., Li, S., Zhao, Y., Pan, L., et al. (2020) · Neurosurgical FOCUS · doi:10.3171/2020.3.focus2067 · Cited by 27
Predictors of quality of life in 102 patients with treated C ushing's disease
Carluccio, A. L., Sundaram, N. K., Chablani, S. V., Amrock, L. G., Lambert, J. K., Post, K. D., & Geer, E. B. (2014) · Clinical Endocrinology · doi:10.1111/cen.12521 · Cited by 33
Diagnosis and Multimodality Management of Cushing’s Disease: A Practical Review
Zada, G. (2013) · International Journal of Endocrinology · doi:10.1155/2013/893781 · Cited by 27
“Surgery remains the primary option for most patients with a new diagnosis of Cushing’s Disease [26].”
BackgroundRamm‐Pettersen, J., Halvorsen, H. L., Evang, J. A., Rønning, P. A., Hol, P. K., Bollerslev, J., Berg–Johnsen, J., & Helseth, E. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0055-9 · Cited by 28
Use of cabergoline for the management of persistent Cushing’s disease in pregnancy
Sek, K. S., Deepak, D. S., & Lee, K. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-217855 · Cited by 27
Liu, X.-H., Feng, M., Zhang, Y., Dai, C., Sun, B., Bao, X., Deng, K., Yao, Y., & Wang, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.01.214 · Cited by 27
Lacroix, A., Gu, F., Schopohl, J., Kandra, A., Pedroncelli, A. M., Jin, L., & Pivonello, R. (2019) · Pituitary · doi:10.1007/s11102-019-01021-2 · Cited by 29
Self-citationMitotane reduces human and mouse ACTH-secreting pituitary cell viability and function
Gentilin, E., Tagliati, F., Terzolo, M., Zoli, M., Lapparelli, M., Minoia, M., Ambrosio, M. R., Uberti, E. C. D., & Zatelli, M. C. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0210 · Cited by 30
Witek, P., Zieliński, G., Szamotulska, K., Maksymowicz, M., & Kamiński, G. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1226 · Cited by 26
Pituitary-Directed Therapies for Cushing’s Disease
Langlois, F., Chu, J. M., & Fleseriu, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00164 · Cited by 28
3 Rationale for treatment and therapeutic options in Cushing's disease
Stewart, P. M., & Petersenn, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(09)70004-1 · Cited by 28
Self-citationCushing's disease due to double pituitary ACTH-secreting adenomas: the first case report
Andrioli, M., Giraldi, F. P., Losa, M., Terreni, M., Invitti, C., & Cavagnini, F. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-140 · Cited by 26
Medical treatment of Cushing's disease: Overview and recent findings
Heaney, A. P. (2009) · International Journal of General Medicine · doi:10.2147/ijgm.s7545 · Cited by 25
M ultiple endocrine neoplasia type 1 ( MEN1 )
Carroll, R. W. (2012) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12046 · Cited by 31
A prospective study of appetite and food craving in 30 patients with Cushing’s disease
Geer, E. B., Lalazar, Y., Couto, L., Cohen, V. V., Lipton, L. R., Shi, W., Bagiella, E., Conwell, I. M., Bederson, J. B., Kostadinov, J., et al. (2015) · Pituitary · doi:10.1007/s11102-015-0690-1 · Cited by 26
Milian, M., Honegger, J. B., Teufel, P., Wolf, A., & Psaras, T. (2013) · Neuroendocrinology · doi:10.1159/000355622 · Cited by 25
Clinical use of pasireotide for Cushing's disease in adults
Boscaro, M., Ceccato, F., & Scaroni, C. M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s37314 · Cited by 36
“17 In this complex scenario of treatment options, it may be difficult for clinical endocrinologists to make the most appropriate choice.”
Self-citation
Metadata
- Authors
- Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., Klibanski, A., Lacroix, A., Lindsay, J. R., Newell-Price, J., Nieman, L. K., Petersenn, S., Sonino, N., Stalla, G. K., Swearingen, B., Vance, M. L., Wass, J. A. H., & Boscaro, M.
- Affiliations
- Massachusetts General Hospital (US)
- St Bartholomew's Hospital (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Cedars-Sinai Medical Center (US)
- Hôpital Cochin (FR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Naples Federico II (IT)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Centre Hospitalier de l’Université de Montréal (CA)
- Altnagelvin Area Hospital (GB)
- University of Sheffield (GB)
- National Institutes of Health (US)
- University of Duisburg-Essen (DE)
- University of Padua (IT)
- Max Planck Institute of Psychiatry (DE)
- University of Virginia Health System (US)
- Churchill Hospital (GB)
- Marche Polytechnic University (IT)
- Corresponding author
- Boscaro, M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2454-2462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3214276
- OpenAlex
- W2147573461
- Cited by
- 853
- References
- 107
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 26 · 2023: 29 · 2022: 40 · 2021: 35 · 2020: 47 · 2019: 59 · 2018: 42 · 2017: 40 · 2016: 44 · 2015: 91 · 2014: 69 · 2013: 74 · 2012: 70
- FWCI
- 38.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- ACTH-dependent Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, Nelson's syndrome, transsphenoidal surgery, pituitary tumor resection, radiotherapy, medical therapy, bilateral adrenalectomy, remission criteria, consensus statement
- MeSH terms
- ACTH Syndrome, Ectopic, Adrenal Insufficiency, Adrenalectomy, Adrenocorticotropic Hormone, Cushing Syndrome, Humans, Hypophysectomy, Metyrapone, Mitotane, Nelson Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.